Insmed Shares Are Trading Higher After Announcing That No Agreement Was Reached Between the Company and AstraZeneca and Insmed Retains Full Worldwide Development and Commercialization Rights for Brensocatib in All Indications Other Than COPD or Asthma...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.